中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
EVALUATION AND ANAL YSIS OF DRUG-USE IN HOSPITALS OF CHINA
2014年
10期
881-883
,共3页
高延秋%张华%陈建丽%孙广信%任英杰
高延鞦%張華%陳建麗%孫廣信%任英傑
고연추%장화%진건려%손엄신%임영걸
血必净注射液%重症肺炎%炎症因子
血必淨註射液%重癥肺炎%炎癥因子
혈필정주사액%중증폐염%염증인자
Xuebijing injection%Severe pneumonia%Inflammatory factors
目的:探讨血必净注射液对重症肺炎患者炎症因子的影响。方法:将126例患者采用随机双盲试验设计分为治疗组和对照组,对照组给予常规抗感染、祛痰、机械通气、对症支持治疗,治疗组在此基础上加用血必净注射液100 ml静脉滴注、2次/d,疗程为14 d。比较2组患者血清中白细胞介素-6(IL-6)、白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)水平,并进行急性肺损伤评分、多器官功能障碍综合征评分( MODS评分)和全身炎症反应综合征评分( SIRS评分)。结果:治疗7 d和14 d后,治疗组患者IL-6、TNF-α、肺损伤评分、MODS评分和SIRS评分比对照组明显下降(P<0?05);2组患者治疗前后及2组间IL-10水平比较均无明显差异。结论:血必净注射液可抑制炎症因子释放,显著改善重症肺炎患者预后。
目的:探討血必淨註射液對重癥肺炎患者炎癥因子的影響。方法:將126例患者採用隨機雙盲試驗設計分為治療組和對照組,對照組給予常規抗感染、祛痰、機械通氣、對癥支持治療,治療組在此基礎上加用血必淨註射液100 ml靜脈滴註、2次/d,療程為14 d。比較2組患者血清中白細胞介素-6(IL-6)、白細胞介素-10(IL-10)、腫瘤壞死因子-α(TNF-α)水平,併進行急性肺損傷評分、多器官功能障礙綜閤徵評分( MODS評分)和全身炎癥反應綜閤徵評分( SIRS評分)。結果:治療7 d和14 d後,治療組患者IL-6、TNF-α、肺損傷評分、MODS評分和SIRS評分比對照組明顯下降(P<0?05);2組患者治療前後及2組間IL-10水平比較均無明顯差異。結論:血必淨註射液可抑製炎癥因子釋放,顯著改善重癥肺炎患者預後。
목적:탐토혈필정주사액대중증폐염환자염증인자적영향。방법:장126례환자채용수궤쌍맹시험설계분위치료조화대조조,대조조급여상규항감염、거담、궤계통기、대증지지치료,치료조재차기출상가용혈필정주사액100 ml정맥적주、2차/d,료정위14 d。비교2조환자혈청중백세포개소-6(IL-6)、백세포개소-10(IL-10)、종류배사인자-α(TNF-α)수평,병진행급성폐손상평분、다기관공능장애종합정평분( MODS평분)화전신염증반응종합정평분( SIRS평분)。결과:치료7 d화14 d후,치료조환자IL-6、TNF-α、폐손상평분、MODS평분화SIRS평분비대조조명현하강(P<0?05);2조환자치료전후급2조간IL-10수평비교균무명현차이。결론:혈필정주사액가억제염증인자석방,현저개선중증폐염환자예후。
OBJECTIVE:To explore the effects of Xuebijing injection on serum inflammatory factors in patients with severe pneumonia( SP) . METHODS:126 patients with SP were randomly divided into two groups, with control group administered with conventional anti-infective and phlegm-expelling agents, mechanical ventilation, symptomatic and supportive treatment, whereas the patients in the treatment group were intravenously administered with 100 ml add-on Xuebijing injection b. i. d for 14 days. Serum interleukin-6 ( IL-6 ) , interleukin-10 ( IL-10 ) and tumor necrosis factor-α( TNF-α) levels in the two groups were compared; scoring for acute lung injury, multiple organs dysfunction syndrome(MODS) and systemic inflammatory response syndrome(SIRS) were performed. RESULTS: At 7 and 14 days of treatment, IL-6 and TNF-αlevels, lung injury score, MODS score and SIRS score in the treatment group were significantly lower than in the control group ( P<0?05 );with regard to IL-10 , no significant differences were noted for both groups before and after treatment or between the two groups. CONCLUSIONS:Xuebijing injection can inhibit the release of inflammatory factors and significantly improve the prognosis of patients with SP.